BRIM Biotechnology, Inc. (TPE:6885)

Market Cap	3.35B -25.1%
Revenue (ttm)	10.60M +427.8%
Net Income	-428.00M
EPS	-3.26
Shares Out	133.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	559,478
Open	25.20
Previous Close	25.15
Day's Range	25.05 - 25.55
52-Week Range	20.05 - 34.30
Beta	0.74
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About BRIM Biotechnology

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that ha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6885

Financial Performance

In 2025, BRIM Biotechnology's revenue was 5.49 million, an increase of 1548.65% compared to the previous year's 333,000. Losses were -436.45 million, 38.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error